GN
Garry Arthur Neil
Chief Executive Officer

Garry Arthur Neil insider trades: Avalo Therapeutics (AVTX) stock purchases

Chief Executive Officer, Avalo Therapeutics Last trade Jun 9, 2023 58 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2014
8
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Garry reports to the SEC

and 2 more companies

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 9, 2023AVTX↑ Buy$14K
Dec 9, 2022AVTX↑ Buy$9K
Dec 10, 2021AVTX↑ Buy$7K
Jun 10, 2021CERC↑ Buy$8K
Dec 10, 2020CERC↑ Buy$8K
Jun 10, 2020CERC↑ Buy$4K
Dec 5, 2019GNMX↑ Buy$275K
Oct 17, 2017GNMX↑ Buy$95K
Oct 6, 2015MDGN↑ Buy$100K
Dec 1, 2014MDGN↑ Buy$100K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AVTX insiders

Open-market trades in the last 12 months

About Garry Arthur Neil's insider trades

Garry Arthur Neil is Chief Executive Officer at Avalo Therapeutics (AVTX). Since Dec 1, 2014, Garry has reported 10 open-market purchases worth $619K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (44 filings), shares withheld for taxes (2 filings), option exercises (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.